首页 | 本学科首页   官方微博 | 高级检索  
检索        

参芪扶正注射液联合SOX方案治疗晚期胃癌临床研究
引用本文:汤锡锋,陈垂海,纪新尊.参芪扶正注射液联合SOX方案治疗晚期胃癌临床研究[J].河南中医,2017,37(9).
作者姓名:汤锡锋  陈垂海  纪新尊
作者单位:三亚市人民医院,海南三亚,572000
摘    要:目的:观察参芪扶正注射液联合SOX方案治疗晚期胃癌的临床疗效及安全性。方法:选取2013年11月—2015年11月本院确诊为晚期胃癌的患者61例,随机分为观察组31例和对照组30例。两组患者均采用SOX方案进行化疗,均给予对症支持治疗,观察组另给予参芪扶正注射液治疗。结果:观察组RR为74.19%,对照组RR为43.33%,观察组优于对照组(χ~2=6.003,P=0.0140.05);观察组DCR为93.55%,对照组DCR为73.33%,观察组优于对照组(χ~2=4.546,P=0.0330.05);观察组TTP、MST优于对照组(P0.01);两组均未发生治疗相关性死亡,其毒副反应以消化道反应、骨髓抑制及周围神经毒性为主,且观察组不良反应发生率低于对照组(P0.05或0.01)。结论:参芪扶正注射液联合SOX方案治疗晚期胃癌的临床疗效较好,不良反应发生率低,提高患者生存质量和延长生存期。

关 键 词:晚期胃癌  参芪扶正注射液  SOX方案  替吉奥胶囊  奥沙利铂

The Clinical Research into Advanced Gastric Cancer Treated with Shenqifuzheng Injection in Combination with SOX Regimen
TANG Xi-feng,CHEN Chui-hai,JI Xin-zun.The Clinical Research into Advanced Gastric Cancer Treated with Shenqifuzheng Injection in Combination with SOX Regimen[J].Henan Traditional Chinese Medicine,2017,37(9).
Authors:TANG Xi-feng  CHEN Chui-hai  JI Xin-zun
Abstract:Objective:To observe the clinical curative effect and safety of Shenqifuzheng Injection (SQFZI) in combination with SOX regimen on advanced gastric cancer.Methods:Sixty-one patients with advanced gastric cancer who were treated in our hospital between Nov.2013 and Nov.2015 were chosen as the research subjects,and were randomly divided into the observation group and the control group,with 31 and 30 cases respectively in each group.The ones in both groups were given SOX regimen for chemotherapy,and symptomatic supportive treatment,then the ones in the observation group were added SQFZI.Results:The observation group's RR was 74.19%,whilt that of the control group was 43.33%,the observation group was better than the control grouP(x2 =6.003,P =0.014 < 0.05).The observation group's DCR was 93.55%,whilt that of the control group was 73.33%,the observation group was better than the control group(x2 =4.546,P =0.033 < 0.05).The observation group's TTP and MST were better than those of the control group (P < 0.0l).There were no treatment-related death in the two groups,and their toxicity to gastrointestinal reactions,bone marrow suppression and peripheral neurotoxicity were clear.The incidence of adverse reaction of the observation group was better than that of the control group (P < 0.05 or 0.01).Conclusion:SQFZI in combination with SOX regimen has a remarkable clinical curative effect on advanced gastric cancer.The incidence of adverse reactions is low,and can improve the patients' quality of life and prolong their survival.
Keywords:advanced gastric cancer  Shenqifuzheng Injection (SQFZI)  SOX regimen  S-1 Capsules  oxaliplatin
本文献已被 CNKI 万方数据 等数据库收录!
设为首页 | 免责声明 | 关于勤云 | 加入收藏

Copyright©北京勤云科技发展有限公司  京ICP备09084417号